BRPI0717135B8 - antagonista peptídico cíclico de somastotatina e composição farmacêutica - Google Patents

antagonista peptídico cíclico de somastotatina e composição farmacêutica

Info

Publication number
BRPI0717135B8
BRPI0717135B8 BRPI0717135A BRPI0717135A BRPI0717135B8 BR PI0717135 B8 BRPI0717135 B8 BR PI0717135B8 BR PI0717135 A BRPI0717135 A BR PI0717135A BR PI0717135 A BRPI0717135 A BR PI0717135A BR PI0717135 B8 BRPI0717135 B8 BR PI0717135B8
Authority
BR
Brazil
Prior art keywords
sstr2
receptor
selective
srif
antagonists
Prior art date
Application number
BRPI0717135A
Other languages
English (en)
Inventor
R Maecke Helmut
E F Rivier Jean
Claude Reubi Jean
Erchegyi Judit
Original Assignee
Salk Inst Biological Studies
Univ Hospital Basel
Univ Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst Biological Studies, Univ Hospital Basel, Univ Bern filed Critical Salk Inst Biological Studies
Publication of BRPI0717135A2 publication Critical patent/BRPI0717135A2/pt
Publication of BRPI0717135B1 publication Critical patent/BRPI0717135B1/pt
Publication of BRPI0717135B8 publication Critical patent/BRPI0717135B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

antagonistas de receptores (sstr2) seletivos de somastina. antagonistas peptídicos de srif, seletivos para sstr2, ao contrário dos outros receptores clonados de srif e que se ligam com alta afinidade ao receptor sstr2 humano clonado, porém que não ativam o receptor, possuem muitas funções úteis. em vista de não se ligarem com afinidade considerável a sstr1, sstr3, sstr4 ou sstr5, sua administração evita possíveis efeitos colaterais não desejados. por bloquearem a função do receptor, podem ser utilizados terapeuticamente para bloquear certos efeitos fisiológicos mediados pelo sstr2. pela incorporação de iodo radioativo ou substância similar nestes antagonistas de srif seletivo de sstr2, é provido um composto marcado que pode ser utilizado em métodos de seleção de fármacos. alternativamente, para uso em terapia, grupamentos altamente radioativos podem ser acoplados em terminal n, formarem complexos ou serem quelados aos mesmos.
BRPI0717135A 2006-10-16 2007-10-15 antagonista peptídico cíclico de somastotatina e composição farmacêutica BRPI0717135B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82963706P 2006-10-16 2006-10-16
US60/829,637 2006-10-16
PCT/US2007/081430 WO2008048942A2 (en) 2006-10-16 2007-10-15 Receptor(sstr2)-selective somatostatin antagonists

Publications (3)

Publication Number Publication Date
BRPI0717135A2 BRPI0717135A2 (pt) 2013-10-15
BRPI0717135B1 BRPI0717135B1 (pt) 2020-09-15
BRPI0717135B8 true BRPI0717135B8 (pt) 2021-05-25

Family

ID=39144622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717135A BRPI0717135B8 (pt) 2006-10-16 2007-10-15 antagonista peptídico cíclico de somastotatina e composição farmacêutica

Country Status (14)

Country Link
US (2) US7960342B2 (pt)
EP (3) EP2383289B1 (pt)
JP (1) JP5295967B2 (pt)
CN (2) CN101631801B (pt)
AU (1) AU2007311137B2 (pt)
BR (1) BRPI0717135B8 (pt)
CA (1) CA2666642C (pt)
DK (1) DK2076535T3 (pt)
ES (2) ES2410207T3 (pt)
HK (1) HK1132515A1 (pt)
PL (3) PL2076535T3 (pt)
PT (1) PT2076535E (pt)
SI (1) SI2076535T1 (pt)
WO (1) WO2008048942A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2076535T3 (da) 2006-10-16 2013-06-10 Salk Inst For Biological Studi Receptor(SSTR2)-selektive somatostatinantagonister
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN108570097A (zh) 2010-08-13 2018-09-25 爱勒让治疗公司 拟肽大环化合物
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
CN104086630B (zh) * 2014-06-25 2016-06-29 天津欧德莱生物医药科技有限公司 一种生长抑素受体激动剂多肽及其应用
CN104045690B (zh) * 2014-06-25 2016-06-08 舟山医院 生长抑素受体激动剂多肽及其应用
CN104045689B (zh) * 2014-06-25 2016-08-24 新乡医学院 一种关于生长抑素受体激动剂多肽及其应用
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
CN104491890A (zh) * 2014-11-21 2015-04-08 北京肿瘤医院 放射性核素标记的新型生长抑素类似物分子探针及其应用
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
BR112018016198A2 (pt) * 2016-02-09 2019-01-22 Cdrd Ventures Inc compostos antagonistas do receptor de somatostatina e métodos de uso do mesmo
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
TW202017600A (zh) * 2018-06-21 2020-05-16 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202015744A (zh) * 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3904594A (en) 1973-07-02 1975-09-09 Salk Inst For Biological Studi Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof
US4372884A (en) 1975-08-06 1983-02-08 The Salk Institute For Biological Studies Pharmaceutically active peptides
US4428942A (en) * 1982-05-17 1984-01-31 The Salk Institute For Biological Studies Analogs of somatostatin
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US5776894A (en) * 1988-12-05 1998-07-07 Novartis Ag Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
EP0752873A4 (en) 1994-02-18 2002-05-15 Mallinckrodt Inc MARKED PEPTIDE COMPOUNDS
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5708135A (en) 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
NZ335879A (en) * 1996-12-04 2000-11-24 Univ Tulane Somatostatin antagonist peptides having a D-amino acid at the second residue
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
US6579967B1 (en) * 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
AU3290302A (en) * 2000-10-20 2002-04-29 Univ Tulane Urotensin-ii agonists and antagonists
EP1372688B1 (en) * 2001-03-08 2008-05-07 The Administrators of The Tulane Educational Fund Somatostatin antagonists
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
CA2461099A1 (en) 2001-09-21 2003-04-10 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
WO2004009614A2 (en) 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
AU2004222531A1 (en) 2003-03-19 2004-09-30 Universitat Bern Radiolabeled conjugates based on substance P and the uses thereof
DK2076535T3 (da) 2006-10-16 2013-06-10 Salk Inst For Biological Studi Receptor(SSTR2)-selektive somatostatinantagonister

Also Published As

Publication number Publication date
AU2007311137A1 (en) 2008-04-24
DK2076535T3 (da) 2013-06-10
BRPI0717135A2 (pt) 2013-10-15
EP2076535A2 (en) 2009-07-08
WO2008048942A3 (en) 2008-09-18
EP2076535B1 (en) 2013-03-06
CA2666642C (en) 2015-11-17
CN103288919B (zh) 2014-11-12
JP2010506943A (ja) 2010-03-04
JP5295967B2 (ja) 2013-09-18
EP2433963B1 (en) 2014-06-04
CA2666642A1 (en) 2008-04-24
CN101631801A (zh) 2010-01-20
US7960342B2 (en) 2011-06-14
ES2410207T3 (es) 2013-07-01
PL2076535T3 (pl) 2013-08-30
EP2383289B1 (en) 2014-10-08
SI2076535T1 (sl) 2013-07-31
WO2008048942A2 (en) 2008-04-24
BRPI0717135B1 (pt) 2020-09-15
EP2433963A1 (en) 2012-03-28
US8501687B2 (en) 2013-08-06
HK1132515A1 (en) 2010-02-26
US20110269683A1 (en) 2011-11-03
CN103288919A (zh) 2013-09-11
EP2383289A1 (en) 2011-11-02
ES2526292T3 (es) 2015-01-09
PT2076535E (pt) 2013-06-12
CN101631801B (zh) 2013-06-05
AU2007311137B2 (en) 2013-06-20
PL2383289T3 (pl) 2015-03-31
US20080260638A1 (en) 2008-10-23
PL2433963T3 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
BRPI0717135B8 (pt) antagonista peptídico cíclico de somastotatina e composição farmacêutica
Virgolini et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors
Manning et al. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on
Sankaran et al. Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini.
Müller et al. Restoration of leptin responsiveness in diet‐induced obese mice using an optimized leptin analog in combination with exendin‐4 or FGF21
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
Agostini et al. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ
DE69230888T2 (de) Somatostatinrezeptoren
Öberg Future aspects of somatostatin-receptor-mediated therapy
Koga et al. Demonstration of specific dopamine receptors on human pituitary adenomas
KR20210024081A (ko) 당뇨병을 위한 gip/glp1 공효능제의 사용 방법
BRPI0410495A (pt) composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento
WO2020092191A1 (en) Protein tyrosine-tyrosine analogs and methods of using the same
PEDERSEN et al. Lys-γ3-melanotropin binds with high affinity to the rat adrenal cortex
Rugarn Radioimmunoassay for rat galanin: immunochemical and chromatographic characterization of immunoreactivity in tissue extracts
O’Dorisio et al. Evolution of neuroendocrine tumor therapy
EP0829011B1 (en) Inhibition of amylin release
Öberg Somatostatin analog octreotide LAR® in gastro–entero–pancreatic tumors
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
Huang et al. Evidence for a gonadotropin-releasing hormone binding protein in goldfish (Carassius auratus) serum
Leaños‐Miranda et al. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients
Coy et al. Somatostatin analogues and multiple receptors: possible physiological roles
Ai et al. Single-and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys
Parker et al. Blockade of pancreatic polypeptide-sensitive neuropeptide Y (NPY) receptors by agonist peptides is prevented by modulators of sodium transport. Implications for receptor signaling and regulation
Streuli et al. Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF